Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

IMetelstat and Azacitidine With or Without Venetoclax GIveN in rElapsed Acute Myeloid Leukemia (IMAGINE Trial)

NCT07320235 is registered in ClinicalTrials.gov with Douglas Tremblay as lead sponsor.

NCT NCT07320235
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07320235 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
IMetelstat and Azacitidine With or Without Venetoclax GIveN in rElapsed Acute Myeloid Leukemia (IMAGINE Trial)
Lead sponsor
Douglas Tremblay
Phase
Phase 1
Overall status
Recruiting
Start date
January 2, 2026
Completion date
June 15, 2035
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed acute myeloid leukemia